a2) United States Patent
`US 9,340,568 B2
`(10) Patent No.:
`May17, 2016
`(45) Date of Patent:
`Casteelet al.
`
`US009340568B2
`
`(54) SOLID FORMSOF AN ANTIVIRAL
`COMPOUND
`
`(71) Applicant: Gilead Pharmasset LLC, Foster City,
`CA (US)
`
`(72)
`
`Inventors: Melissa Jean Casteel, Foster City, CA
`(US); Kathleen Dashner, Foster City,
`CA (US); Hyuk-Jun Jung, Shiheung-si
`(KR); Mun Sik Seo, Shiheung-si (KR);
`Bing Shi, Redwood City, CA (US); Fang
`Wang, Foster City, CA (US); Vahid Zia,
`Foster City, CA (US)
`
`(73) Assignee: GILEAD PHARMASSET LLC, Foster
`City, CA (US)
`
`(*) Notice:
`
`Subject to any disclaimer, the term of this
`patent is extended or adjusted under 35
`U.S.C. 154(b) by 0 days.
`
`(21) Appl. No.: 14/563,639
`
`(22)
`
`Filed:
`
`Dec. 8, 2014
`
`(65)
`
`Prior Publication Data
`
`US 2015/0175646 Al
`
`Jun. 25, 2015
`
`Related U.S. Application Data
`
`(60) Provisional application No. 61/920,371, filed on Dec.
`23, 2013.
`
`(51)
`
`Int. Cl.
`AOIN 43/04
`AGIK 31/70
`CO7H 19/10
`AGIK 31/7052
`AGIK 31/7064
`AGIK 31/706
`AGIK 31/7068
`AGIK 31/7072
`CO7F 9/6558
`CO7H 19/06
`(52) U.S.CL
`CPC veeceeesseeee CO7H 19/10 (2013.01); A61K 31/706
`(2013.01); A6LK 31/7052 (2013.01); A6IK
`31/7064 (2013.01); A6LK 31/7068 (2013.01);
`
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`
`AG6LK 31/7072 (2013.01); CO7F 9/65586
`(2013.01); CO7H 19/06 (2013.01)
`(58) Field of Classification Search
`None
`
`See application file for complete search history.
`
`(56)
`
`References Cited
`U.S. PATENT DOCUMENTS
`
`7,964,580 B2
`8,618,076 B2
`8,642,756 B2*
`
`6/2011 Sofia et al.
`12/2013 Rossetal.
`2/2014 Ross wees C07H 19/10
`536/117
`
`OTHER PUBLICATIONS
`
`Int’l Search Report—Writte Opinion Dated Jul. 2, 2015 For PCT/
`US2014/069123.
`
`* cited by examiner
`
`Primary Examiner — Patrick Lewis
`
`(57)
`
`ABSTRACT
`
`Crystalline solid forms of the anti-HCV compound(S)-iso-
`propyl 2-((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropy-
`rimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydro-
`furan-2-
`yl)methoxy)(phenoxy)phosphorylamino)
`propanoate (CompoundJ) are described
`
`(Compound I)
`
`
`
`Also provided are processes of making and methods of using
`the crystalline forms.
`
`10 Claims, 10 Drawing Sheets
`
`(cid:42)(cid:76)(cid:79)(cid:72)(cid:68)(cid:71)(cid:3)(cid:21)(cid:19)(cid:19)(cid:25)
`Gilead 2006
`(cid:44)(cid:16)(cid:48)(cid:36)(cid:46)(cid:3)(cid:89)(cid:17)(cid:3)(cid:42)(cid:76)(cid:79)(cid:72)(cid:68)(cid:71)
`I-MAK v. Gilead
`(cid:44)(cid:51)(cid:53)(cid:21)(cid:19)(cid:20)(cid:27)(cid:16)(cid:19)(cid:19)(cid:22)(cid:28)(cid:19)
`IPR2018-00390
`
`

`

`U.S. Patent
`
`May17, 2016
`
`Sheet 1 of 10
`
`US 9,340,568 B2
`
`ge
`
`
`
`
`
`
`O00P
`
`rQ00€
`
`r0002
`
`—OOOL
`
`
`
`
`LOld
`
`

`

`U.S. Patent
`
`May17, 2016
`
`Sheet 2 of 10
`
`US 9,340,568 B2
`
`steno0OTOfGFOFOSO89OfO086QOOTOFTO2TOFTOFTOSTO97Ot_eer06002
`
`
`(wudd)qiusjediways
`
`
`
`
`rodeenrenneneedennheenintitetabaimet
`
`¢Old
`
`sesame:Lucene,
`
`|
`
`
`

`

`U.S. Patent
`
`May17, 2016
`
`Sheet 3 of 10
`
`US 9,340,568 B2
`
`povcheceretntnttetesnn fnn mtinitcni n
`
`i
`
`i
`
`}
`
`|
`
`} i
`
`i: I
`
`| :I' i i:i
`
`+ 5
`
` ssaeizahagaaOreaRrestosONNORieeeeal
`SEASpAeNEARINGeSetCOREEGGSERSIAREEIEEOSINIRESOSEALE,
`Ajisuajul URWY
`
`
`
`
`
`bthghnmniainGabigoOONOMaadtieutieerdfmel,ps:
`
`54:i
`
`
`
`
`
`(1-9)yiusUpwey
`
`
`
`
`€Old
`
`
`
`o00zO0Seooocoose
`
`
`
`
`

`

`U.S. Patent
`
`May17, 2016
`
`Sheet 4 of 10
`
`US 9,340,568 B2
`
`002O8LO9LOL0€LOOL0809OVPatennLo
`
`
`
`
`
`nusclinininsidenmissiticiininsintisnidiainRaiabaresacestaccessofieatlrvercamthenicereasctachaeseatesccgseacse
`arcanemrtentiRERRASSNSSSSeAERteenceaguoocnelasaj0
`|aeBPSPG——9.89641——
`|DollbZh
`r[ef:Loo
`
`nnn"
`
`
`
`(B/AA) MO} Ye8H
`
`AaaHAAAANAAEtaconite
`cranewailccs
`scot
`eatenmm entTEE EC
`sgnnrsonesn
`as
`
`
`
`
`
`(9,)sunjeisdwa,
`
`¥Ola
`
`

`

`U.S. Patent
`
`May17, 2016
`
`Sheet 5 of 10
`
`US 9,340,568 B2
`
`
`
`
`
`
`
`
`
`
`
`[d.s'szcdwal10]Wi9UI0S]SAG
`
`OOFo668o£O39O¢OFoeGeOL8)
`
`
`
`uoydioser~o~UOICLIOSDIYgpm
`
`|ozo|sz°0+of'0|Se°0|oro|sro
`
`sro
`(%) sseyyj ul eHueyD
`
`|soo+Oo
`
`
`
`(%)Aipiwnysayejayjabiel
`
`
`
`
`
`SOla
`
`
`
`

`

`U.S. Patent
`
`May17, 2016
`
`Sheet 6 of 10
`
`US 9,340,568 B2
`
`Fovebnbeeettboga ||EVVPyroETVySey”|
`
`
`
`|((nQ)1addoa)[eyeyiz,]uonisog
`ge96+ezeOF82
`
`
`
`|
`
`ry
`
`|
`
`(
`
`9Old
`
`
`
`0009
`
`000g
`
`000”
`
`000€
`
`0002
`
`gjunoy
`
`

`

`U.S. Patent
`
`May17, 2016
`
`Sheet 7 of 10
`
`US 9,340,568 B2
`
`
`
`‘0OFOfOFOFOSO09OLO806OOLOTEOZEOFTObTOSEOSTOZTO8TO61007
`
`
`
`
`
`
`
`
`
`
`
`emaccxccoreneerasereteacre:emismined-ebymenanteNwntcnthamnraatienimntaticeennctnttinnesisticetabacibaenemaeseman
`
`Z9Id
`
`
`
`
`
`(uidd)yiyspeniways
`
`
`
`
`
`
`
`
`
`
`
`

`

`U.S. Patent
`
`May17, 2016
`
`Sheet 8 of 10
`
`US 9,340,568 B2
`
`See
`
`satietyitiascree
`
`Se
`
`“sosmesnoammaNBS
`
`streamerIOISEERaonanpnnse
`
`eee
`crmi
`sareeOYFaeh
`
`
`
`(1-u9)yiysUeLUeY
`
`8Dia
`
`aad
`
`oRse
`
`oo0t
`
`onse
`
`A
`
`
`
`Se‘
`
`hiheeaes:‘Seed»itdoy2
`iwi+z¢
`.woeye“9
`
`
`
`senatemrnnnsping
`|
`sconesco
`
`gb
`
`Ls
`
`‘st
`
`‘Sh
`
`oh
`
`ZL
`
`“bb
`
`“OL
`
`Aysuejul wewey
`
`tgpeeasdreRIRAOBAIARODODNEADSNMMGHRPCIERLE
`
`
`
`
`
`

`

`U.S. Patent
`
`May 17, 2016
`
`Sheet 9 of 10
`
`US 9,340,568 B2
`
`
`002=—OSkSs«orloz)0010809orOz
`
`
`
`
`
`
`
`
`
`
`
`tEneeeBeeenernomenlameXieBammeronionsertsSie1SmetepreBeetlhshoesoilseeweeornamentBoonenbienrneBrennaborersetBveencnansan,ogeeanusgeniooibo
`DollEEL:|t
`
`|
`
`|
`
`|
`
`wo
`9
`(B/AA) MO|-| Jee}
`
`2a
`
`n
`
`i
`pela
`
`
`
`(D,)ainjeradwia,
`
`6Ola
`
`468LEL
`
`Byrge'99
`
`4|
`
`
`

`

`U.S. Patent
`
`May 17, 2016
`
`Sheet 10 of 10
`
`US 9,340,568 B2
`
`
`
`osOf09O¢OFoegeaL6*memene000
`
`
`uondiosec]-o—uondiospy—@—i
`
`
`
`JOWA9Y}OS]SAG
`
`19g'0
`
`rSpo
`
`,OPO
`
`onesoo
`
`|seo
`
`S20
`;0&0
`o20
`(%} sseyy ul aBueUy
`
`OD
`
`
`
`
`
`
`
`(%)Aipiunyaanelayyobsey
`
`OLOld
`
`
`

`

`US 9,340,568 B2
`
`1
`SOLID FORMSOF AN ANTIVIRAL
`COMPOUND
`
`CROSS REFERENCE
`
`This application claims the benefits of U.S. Provisional
`Application No. 61/920,371, filed on Dec. 23, 2013, the entire
`disclosure of which is incorporated herein by reference.
`
`BACKGROUND
`
`Hepatitis C is recognized as a chronic viral disease of the
`liver. Although drugs targeting the liver are in wide use and
`have shownefficacy, toxicity and other side effects have
`limitedtheir usefulness. Inhibitors ofhepatitis C virus (HCV)
`are useful to limit the establishmentand progression of infec-
`tion by HCV as well as in diagnostic assays for HCV.
`The compound (S)-isopropyl 2-((S)-(((2R,3R,4R,5R)-5-
`(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hy-
`droxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)
`as
`phosphorylamino)propanoate,
`designated
`herein
`CompoundI, also known as Sofosbuvir, is an effective anti-
`HCV agent and is described in International Publication
`Numbers WO 2008/121634 and WO 2011/123654, and in
`USS. Pat. Nos. 7,964,580 and 8,618,076. While certain crys-
`talline forms of CompoundI have been reported, Compound
`I wasnot heretofore knownin the crystalline forms described
`herein.
`
`10
`
`30
`
`SUMMARY
`
`Thepresent disclosure relates to crystalline solid forms of
`the compound(S)-isopropy! 2-((S)-((2R,3R,4R,5R)-5-(2,4-
`dioxo-3,4-dihydropyrimidin- 1 (2H)-yl)-4-fluoro-3-hydroxy-
`4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phospho-
`rylamino)propanoate (CompoundI)
`
`(Compound I)
`
`40
`
`0
`
`NH
`
`45
`
`50
`
`55
`
`60
`
`processes for making the crystalline solid forms of Com-
`poundI, and their therapeutic methods of use.
`The present disclosure provides two crystalline forms of
`CompoundI, referred to herein as Form 7 and Form 8. Forms
`7 and 8 may be characterized and distinguished from other
`solid forms of the same compoundusing various analytical
`techniques including, but not limited to, X-ray powder dif-
`fraction (XRPD), solid-state nuclear magnetic resonance
`(NMR,or 17°C SSNMR), Raman spectroscopy, differential
`scanning calorimetry (DSC), dynamic vapor sorption (DVS),
`and thermogravimetric analysis (TGA). The disclosure also
`provides processes for making the crystalline forms and
`methods for using them in the treatment of HCV.
`
`2
`One embodiment is a crystalline form of (S)-isopropyl
`2-((S)-((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimi-
`din-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofu-
`ran-2-yl)methoxy)(phenoxy)phosphorylamino) propanoate
`(Compound J) characterized by an XRPD diffractogram com-
`prising at least two peaks chosen from the followinglist: 12.6,
`13.5, 16.9, and 17.3 degrees two-theta (°20), +0.2° 20.
`Another embodimentis crystalline Compound I character-
`ized by an XRPD diffractogram comprising peaks at 12.6 and
`13.5 °20+0.2° 28. Another embodimentis crystalline Com-
`poundI characterized by an XRPD diffractogram comprising
`peaks at 12.6, 13.5, and 17.3 °20+0.2° 26. Another embodi-
`mentis crystalline Compound I characterized by an XRPD
`diffractogram comprising peaks at 12.6, 13.5, 16.9, and
`17.3 °20+0.2° 20. These crystalline forms of CompoundI are
`referred to as CompoundI, Form 7.
`Another embodimentis a crystalline form of Compound I
`characterized by an XRPD diffractogram comprisingatleast
`two peaks chosen from the followinglist: 8.6, 9.2, 14.2, 15.6,
`16.0, 17.1, 17.5, 18.1, 19.8, and 25.6 °26+0.2° 26. Another
`embodimentis crystalline Compound I characterized by an
`XRPD spectrum comprising peaks
`at 8.6,
`9.2
`and
`17.1 °20+0.2° 20. These crystalline forms of CompoundI are
`referred to as CompoundI, Form 8.
`In another embodiment, provided herein is a method of
`treating a human subject infected with hepatitis C virus com-
`prising administering to the human subject a therapeutically
`effective amount of Compound I, Form 7 or CompoundI,
`Form 8. In another embodiment, provided herein is a method
`of treating a human subject infected with hepatitis C virus
`comprising administering to the human subject a pharmaceu-
`tical composition comprising a therapeutically effective
`amount of Compound I, Form 7 or CompoundI, Form 8 and
`a pharmaceutically acceptable excipient.
`Another embodiment is a pharmaceutical composition
`comprising CompoundI, Form 7 or CompoundI, Form 8 and
`a pharmaceutically acceptable excipient.
`In still a further embodimentis a crystalline compound as
`defined herein or a pharmaceutical composition comprising
`the same for the treatment of a human subject infected by
`hepatitis C virus, use of the crystalline compoundas defined
`herein or the pharmaceutical composition comprising the
`same for the treatment of a human subject infected by hepa-
`titis C virus, use ofthe crystalline compoundas defined herein
`or the pharmaceutical composition comprising the same for
`the manufacture of a medicament for the treatment of a
`human subject infected by hepatitis C virus, and use of a
`crystalline compoundas defined herein or a pharmaceutical
`composition comprising the samein therapy.
`
`BRIEF DESCRIPTION OF THE DRAWINGS
`
`FIG. 1 is an XRPD diffractogram of CompoundI, Form 7.
`FIG. 2 isa ‘°C SSNMRspectrum of CompoundI, Form 7.
`FIG. 3 is an FT-Raman spectrum of CompoundI, Form 7.
`FIG. 41s a DSC plot of CompoundI, Form 7.
`FIG. 5 is a DVS plot of CompoundI, Form 7.
`FIG. 6 is an XRPD diffractogram of CompoundI, Form 8.
`FIG. 7 isa ‘°C SSNMRspectrum of CompoundI, Form 8.
`FIG. 8 is an FT-Raman spectrum of CompoundI, Form 8.
`FIG. 9 is a DSC plot of CompoundI, Form 8.
`FIG. 10 is a DVS plot of Compound I, Form 8.
`
`DETAILED DESCRIPTION
`
`As usedin the present specification, the following words
`and phrases are generally intended to have the meaningsas set
`forth below, except to the extent that the context in which they
`are used indicates otherwise.
`
`

`

`US 9,340,568 B2
`
`3
`The term “therapeutically effective amount” refers to an
`amountthat is sufficient to effect treatment, as defined below,
`when administered to a humanin need of such treatment. The
`
`4
`embodimentis crystalline Compound I, Form 7, character-
`ized by an XRPD diffractogram substantially as shown in
`FIG. 1.
`
`therapeutically effective amount will vary depending upon
`the human subject being treated, the weight and age of the
`human subject, the severity of the disease condition, the man-
`ner of administration and the like, which can readily be deter-
`mined by oneof ordinary skill in the art.
`One embodiment
`is crystalline (S)-isopropyl 2-(((S)-
`((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1
`(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)
`methoxy)(phenoxy)phosphoryeamino)
`propanoate
`(Compound I, Form 7) characterized by an X-ray powder
`diffractogram comprising at least three peaks chosen from the
`following list: 8.2, 10.5, 12.6, 17.0, 17.3, 19.5, 20.2, 21.0,
`23.4, and 27.3 degrees two-theta (°20)+0.2° 28. Another
`embodimentis crystalline Compound I, Form 7, character-
`ized by an XRPD diffractogram comprising at least two peaks
`chosen from the following list: 12.6, 13.5, 16.9, and
`17.3 °20+0.2° 28. Another embodimentis crystalline Com-
`pound I, Form 7, characterized by an XRPD diffractogram
`comprising peaks at 12.6 and 13.5 °20+0.2° 20. Another
`embodimentis crystalline Compound I, Form 7, character-
`ized by an XRPD diffractogram comprising peaks at 12.6,
`13.5, and 17.3 °20+0.2° 20. Another embodimentis crystal-
`line Compound I, Form 7, characterized by an XRPD
`diffractogram comprising peaks at 12.6, 13.5, 16.9, and
`17.3 °20+0.2° 28. Another embodimentis crystalline Com-
`pound I, Form 7, characterized by an XRPD diffractogram
`comprising at least three peaks chosen from the followinglist:
`8.2, 10.5, 12.6, 13.5, 16.9, 17.0, 17.3, 19.5, 20.2, 21.0, 23.4,
`and 27.3 °20+0.2° 20. Another embodimentis crystalline
`Compound I, Form 7, characterized by an XRPD diffracto-
`gram comprisingat least five peaks chosen from the follow-
`ing list: 8.2, 10.5, 12.6, 13.5, 16.9, 17.0, 17.3, 19.5, 20.2, 21.0,
`23.4, and 27.3 °20+0.2° 20. Another embodimentis crystal-
`line CompoundI, Form 7, characterized by an XRPD diffrac-
`togram comprising the following peaks: 8.2, 10.5, 12.6, 13.5,
`16.9, 17.0, 17.3, 19.5, 20.2, 21.0, 23.4, and 27.3 °20+0.2° 20.
`Another embodimentis crystalline CompoundI, Form 7,
`characterized by an XRPD diffractogram comprisingat least
`three d-spacing values from the followinglist: 10.8, 8.4, 7.1,
`6.6, 5.2, 5.1, 4.6, 4.4, 4.2, 3.8 and 3.3 angstroms (A). In
`another embodiment, the crystalline CompoundI, Form 7 is
`characterized by at least two of the following d-spacing val-
`ues: 7.1, 6.6, 5.2, 5.1 angstroms (A). Ina further embodiment,
`the crystalline Compound, Form 7 is characterized by d-spac-
`ing valuesat 7.1 and 6.6 angstroms(A). Another embodiment
`is crystalline Compound I, Form 7, characterized by an
`XRPDdiffractogram comprising d-spacing valuesat 7.1, 6.6,
`and 5.1 angstroms (A). Another embodimentis crystalline
`Compound I, Form 7, characterized by an XRPD diffracto-
`gram comprising d-spacing values at 7.1, 6.6, 5.2, and 5.1
`angstroms (A). Another embodiment is crystalline Com-
`pound I, Form 7, characterized by an XRPD diffractogram
`comprising at least five d-spacing values from the following
`list: 10.8, 8.4, 7.1, 6.6, 5.2, 5.1, 4.6, 4.4, 4.2, 3.8 and 3.3
`angstroms (A). Therelationship between peak positions and
`d-spacing values for Form 7 is found in Table 1 and the
`paragraph immediately following it.
`Another embodimentis crystalline CompoundI, Form 7,
`characterized by an XRPD diffractogram having peak posi-
`tions (28 values) substantially as listed for Form 7 in Table 1.
`Another embodiment is crystalline Compound I, Form 7,
`characterized by an XRPD diffractogram having d-spacing
`values substantially as listed for Form 7 in Table 1. Another
`
`10
`
`15
`
`20
`
`25
`
`30
`
`35
`
`40
`
`45
`
`50
`
`55
`
`60
`
`65
`
`In another embodiment, CompoundI, Form 7 is character-
`ized by a '*C SSNMRspectrum comprising peaks at 18.6,
`164.5, and 171.8 ppm. In another embodiment,
`the °C
`SSNMRspectrum further comprises peaks at 21.5, 68.7,
`81.7, 102.8, and 151.4 ppm. In another embodiment, Com-
`pound I, Form 7 is characterized by a ‘*C SSNMRspectrum
`substantially as shown in FIG.2.
`In another embodiment, CompoundI, Form 7 1s character-
`ized by an FT-Ramanspectrum comprising peaksat 748, 774,
`1006, 1216, and 1717 cm™!. In another embodiment, the
`FT-Raman spectrum further comprises peaks at 545, 616,
`1027, 1372, 2949, and 2988 cm7!. In another embodiment,
`CompoundI, Form 7 is characterized by an FT-Raman spec-
`trum substantially as shown in FIG.3.
`In another embodiment, CompoundI, Form 7 1s character-
`ized by a differential scanning calorimetry (DSC) endotherm
`with an onset at 119-120° C. In another embodiment, Com-
`poundI, Form 7 is characterized by a DSC endotherm with a
`peak at about 122° C. In another embodiment, the DSC curve
`is substantially as shown in FIG.4.
`In another embodiment, CompoundI, Form 7 1s character-
`ized by achange in mass ofabout 0.15% at arelative humidity
`(RH) of 90% (sorption cycle 1) as measured by dynamic
`vapor sorption (DVS). In another embodiment, the DVS is
`substantially as shown in FIG.5.
`In another embodiment, CompoundI, Form 7 1s character-
`ized by at least two of the following:
`an XRPD spectrum comprising peaksat 12.6 and 13.5 °20;
`a ‘°C SSNMRspectrum comprising peaks at 18.6, 164.5,
`and 171.8 ppm;
`an FT-Raman spectrum comprising peaks at 748, 774,
`1006, 1216, and 1717 cm™!; and
`a DSC endotherm with an onset at 119-120° C.
`
`Tn another embodiment, CompoundI, Form 7 is characterized
`by an XRPD spectrum comprising peaksat 12.6 and 13.5, and
`a'°C SSNMRspectrum comprising peaks at 18.6, 164.5, and
`171.8 ppm. In another embodiment, CompoundI, Form 7 is
`characterized by an XRPD spectrum comprising peaks at
`12.6, 13.5, and 17.3, anda °C SSNMRspectrum comprising
`peaks at 18.6, 164.5, and 171.8 ppm.In another embodiment,
`CompoundI, Form 7 is characterized by an XRPD spectrum
`comprising peaksat 12.6, 13.5, 16.9, and 17.3 °20, anda 1°C
`SSNMRspectrum comprising peaksat 18.6, 21.5, 68.7, 81.7,
`102.8, 164.5, 151.4 and 171.8 ppm.
`One embodiment is a process for making CompoundI,
`Form 7, comprising contacting (S)-isopropyl 2-(((S)-((2R,
`3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-
`fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)
`(phenoxy)phosphoryl)amino) propanoate with a solvent
`comprising isopropyl acetate and heptane, whereby Com-
`pound I, Form 7 is formed. In another embodiment, the sol-
`vent comprises THF. In another embodiment, the process
`further comprises seeding with a seed crystal of CompoundI,
`Form 7. In another embodiment, the process further com-
`prises isolating Compound I Form 7.
`Another embodimentis crystalline (S)-isopropyl 2-(((S)-
`(C((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1
`(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)
`methoxy)(phenoxy)phosphory])amino)
`propanoate
`(Compound I, Form 8) characterized by an X-ray powder
`diffractogram comprising atleast three ofthe following peaks
`chosen from the followinglist: 8.6, 9.2, 14.2, 15.6, 16.0, 17.1,
`17.5, 18.1, 19.8, and 25.6 °20+0.2° 20. Another embodiment
`is crystalline Compound I, Form 8, characterized by an
`
`

`

`US 9,340,568 B2
`
`45
`
`6
`5
`One embodiment is a process for making Compound I,
`XRPDdiffractogram comprising at least 5 peaks chosen from
`Form 8, comprising contacting (S)-isopropyl 2-(((S)-((2R,
`the following list: 8.6, 9.2, 14.2, 15.6, 16.0, 17.1, 17.5, 18.1,
`3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-
`19.8, and 25.6 °20+0.2° 20. Another embodimentis crystal-
`fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)
`line CompoundI, Form 8, characterized by an XRPD diffrac-
`(phenoxy)phosphoryl)amino) propanoate with a solvent
`togram comprising peaks at 8.6, 9.2 and 17.1 °20+0.2° 28.
`comprising isopropyl acetate, whereby CompoundI, Form 8
`Another embodimentis crystalline CompoundI, Form 8,
`is formed. In another embodiment, the process further com-
`characterized by an XRPD diffractogram comprising d-spac-
`ing values at 10.3, 9.6, and 5.2 angstroms (A). In yet another
`prises seeding with a seed crystal of CompoundI, Form 8. In
`
`embodiment, the crystalline CompoundI, Form8hasatleast another embodiment, the process further comprises isolating
`three of the following d-spacing: 10.3, 9.6, 6.3, 5.7, 5.5, 5.2,
`CompoundI, Form 8.
`5.1, 4.9, 4.5, and 3.5 angstroms(A). In still another embodi-
`Forms 7 and 8 of CompoundI provided in accordance with
`ment, the crystalline CompoundI, Form 8 hasatleast five of
`the present disclosure may be administered in the form of
`the following d-spacing: 10.3, 9.6, 6.3, 5.7, 5.5, 5.2, 5.1, 4.9,
`pharmaceutical compositions. This disclosure therefore pro-
`4.5, and 3.5 angstroms (A). Therelationship between peak
`vides pharmaceutical compositionsthat contain, as the active
`positions and d-spacing values for Form 8 is found in Table 1.
`ingredient, one or more of Forms 7 and 8 of CompoundI and
`Another embodiment is crystalline Compound I, Form 8,
`one or more pharmaceutically acceptable excipients, carriers,
`characterized by an XRPD diffractogram having peak posi-
`including inert solid diluents andfillers, diluents, including
`tions (28 values) substantially as listed for Form 8 in Table 1.
`sterile aqueous solution and various organic solvents, perme-
`Another embodiment is crystalline Compound I, Form 8,
`ation enhancers, solubilizers and adjuvants. The pharmaceu-
`characterized by an XRPD diffractogram having d-spacing
`tical compositions may be administered alone or in combina-
`values substantially as listed for Form 8 in Table 1. Another
`tion with other therapeutic agents. Such compositions are
`embodimentis crystalline Compound I, Form 8, character-
`prepared in a manner well known in the pharmaceutical art
`ized by an XRPD diffractogram substantially as shown in
`(see, e.g., Remington’s Pharmaceutical Sciences, Mace Pub-
`FIG.6.
`lishing Co., Philadelphia, Pa. 17th Ed. (1985); and Modern
`
`In another embodiment, CompoundI, Form8is character- Pharmaceutics, Marcel Dekker, Inc. 3rd Ed. (G. S. Banker &
`ized by a ‘3C SSNMRspectrum comprising peaksat 23.5,
`C. T. Rhodes, Eds.).
`70.1, and 152.4 ppm.
`In another embodiment,
`the ‘°C
`In one embodiment, provided herein is a pharmaceutical
`SSNMRspectrum further comprises peaks at 22.2, 71.6,
`composition comprising CompoundI, Form 7 and a pharma-
`78.8, 118.6 and 172.2 ppm. In another embodiment, Com-
`ceutically acceptable carrier. In another embodiment, pro-
`poundI, Form8is characterized by a '5C solid state nuclear
`vided herein is a pharmaceutical composition comprising
`magnetic resonance spectrum substantially as shown in FIG.
`CompoundI, Form 8 and a pharmaceutically acceptable car-
`7.
`rier. In various embodiments, a pharmaceutical composition
`
`In another embodiment, CompoundI, Form8is character- can comprise Compound I in more than one solid form. For
`ized by an FT-Ramanspectrum comprising peaksat 628, 759,
`example, a pharmaceutical composition can comprise Com-
`1029, 1224, and 1701 cm™!. In another embodiment, the
`pound I, Form 7 at about 1 to about 100 percent (wt/wt) ofthe
`FT-Raman spectrum further comprises peaks at 221, 290,
`total amount of Compound1. For example, a pharmaceutical
`543, 1397, 2994, and 3076 cm™!. In another embodiment,
`composition can comprise CompoundI, Form 7 at about 1 to
`CompoundI, Form 8 is characterized by an FT-Raman spec-
`about 40 percent of the total amount of Compound 1. For
`trum substantially as shown in FIG.8.
`example, a pharmaceutical composition can comprise Com-
`40
`
`In another embodiment, CompoundI, Form8is character- pound I, Form 7 at about 1 to about 20 percent(i.e. about 1
`ized by a differential scanning calorimetry (DSC) endotherm
`percent, about 2 percent, about 3 percent, about 4 percent,
`with an onset at 131-132° C. In another embodiment, Com-
`about 5 percent, about 6 percent, about 7 percent, about 8
`poundI, Form 8 is characterized by a DSC endotherm with a
`percent, about 9 percent, about 10 percent, about 11 percent,
`peak at about 133° C. In another embodiment, the DSC curve
`about 12 percent, about 13 percent, about 14 percent, about 15
`is substantially as shownin FIG.9.
`percent, about 16 percent, about 17 percent, about 18 percent,
`
`In another embodiment, CompoundI, Form8is character- about 19 percent, about 20 percent) of the total amount of
`ized by achange in mass ofabout 0.17% at a relative humidity
`Compound 1. By way offurther example, a pharmaceutical
`of 90% relative humidity, (sorption cycle 1) as measured by
`composition can comprise CompoundI, Form 8 at about 1 to
`dynamic vapor sorption (DVS). In another embodiment, the
`about 100 percent (wt/wt) ofthe total amount ofCompound 1.
`DVSis substantially as shown in FIG. 10.
`For example, a pharmaceutical composition can comprise
`
`In another embodiment, CompoundI, Form8is character- CompoundI, Form 8 at about 1 to about 40 percentofthe total
`ized by at least two of the following:
`amount of CompoundI. For example, a pharmaceutical com-
`an XRPD spectrum comprising peaks at 8.6, 9.2 and
`position can comprise Compound I, Form 8 at about 1 to
`17.1 °20;
`about 20 percent(i.e. about 1 percent, about 2 percent, about
`a ‘°C SSNMRspectrum comprising peaks at 23.5, 70.1,
`3 percent, about 4 percent, about 5 percent, about 6 percent,
`and 152.4 ppm;
`about 7 percent, about 8 percent, about 9 percent, about 10
`an FT-Raman spectrum comprising peaks at 628, 759,
`percent, about 11 percent, about 12 percent, about 13 percent,
`1029, 1224, and 1701 cm™'; and
`about 14 percent, about 15 percent, about 16 percent, about 17
`a DSC endotherm with an onset at 131-132° C.
`percent, about 18 percent, about 19 percent, about 20 percent)
`of the total amount of Compound1.
`Form 7 and Form 8 of Compound I may be administered
`orally or formulated for oral administration. Administration
`maybe via capsule or enteric coated tablets or the like. In
`making the pharmaceutical compositions that include atleast
`one compounddescribedherein, the active ingredient is usu-
`ally diluted by an excipient and/or enclosed within such a
`carrier that can be in the form of a capsule, sachet, paper or
`
`In another embodiment, CompoundI, Form 8 is characterized
`by an XRPDspectrum comprising peaksat 8.6, 9.2 and 17.1
`°20 and a ‘°C SSNMRspectrum comprising peaks at 23.5,
`70.1, and 152.4 ppm. In another embodiment, CompoundI,
`Form 8 is characterized by an XRPD spectrum comprising
`peaks at 8.6, 9.2 and 17.1 °20 and a ‘°C SSNMRspectrum
`comprising peaks at 22.2, 23.5, 70.1, 71.6, 78.8, 118.6, 152.4
`and 172.2 ppm.
`
`50
`
`55
`
`

`

`US 9,340,568 B2
`
`10
`
`15
`
`20
`
`25
`
`30
`
`7
`other container. Whenthe excipient serves as a diluent, it can
`be in the form of a solid, semi-solid or liquid material (as
`above), which acts as a vehicle, carrier or medium for the
`active ingredient. Thus, the compositions can be in the form
`of tablets, pills, powders, lozenges, sachets, cachets, elixirs,
`suspensions, emulsions, solutions, syrups, aerosols (as a solid
`or in a liquid medium), ointments, soft and hard gelatin cap-
`sules, sterile injectable solutions andsterile packaged pow-
`ders.
`
`8
`tical unit dosage forms comprise from about 10 mg to about
`1000 mg of CompoundI, which may contain from about1 to
`about 99 percent of Form 7 or Form 8. In various embodi-
`ments, the pharmaceutical dosage form comprises about 50,
`or about 100, or about 150, or about 200, or about 250, or
`about 300, or about 350, or about 400, or about 450, or about
`500, or about 550, or about 600, or about 650, or about 700, or
`about 750, or about 800 mg of Compound I. In a further
`embodiment,
`the pharmaceutical dosage form comprises
`about 400 mg of CompoundI. In one embodiment, a phar-
`Some examplesof suitable excipients include lactose, dex-
`maceutical dosage form comprises about 400 mg of Com-
`trose, sucrose, sorbitol, mannitol, starches, gum acacia, cal-
`pound I, wherein the amount of Form 7 is from about 1 to
`cium phosphate, alginates, tragacanth, gelatin, calcium sili-
`about 100 percentof the total amount of CompoundI. In one
`cate, microcrystalline
`cellulose,
`polyvinylpyrrolidone,
`embodiment, a pharmaceutical dosage form comprises about
`cellulose, sterile water, syrup and methy]cellulose. The for-
`400 mg ofCompoundI, wherein the amount ofForm 7 is from
`mulations can additionally include: lubricating agents such as
`about 1 to about 40 percentofthe total amount of Compound
`talc, magnesium stearate and mineral oil; wetting agents;
`I. In one embodiment, a pharmaceutical dosage form com-
`emulsifying and suspending agents; preserving agents such
`prises about 400 mg of Compound IJ, wherein the amount of
`as methyl and propylhydroxy-benzoates; sweetening agents;
`Form 7 is from about 1 to about 20 percent (i.e. about 1
`and flavoring agents.
`percent, about 2 percent, about 3 percent, about 4 percent,
`In some embodiments, the compositions are formulated in
`about 5 percent, about 6 percent, about 7 percent, about 8
`a unit dosage form. The term “unit dosage forms”refers to
`percent, about 9 percent, about 10 percent, about 11 percent,
`physically discrete units suitable as unitary dosages for
`about 12 percent, about 13 percent, about 14 percent, about 15
`human subjects and other mammals, each unit containing a
`percent, about 16 percent, about 17 percent, about 18 percent,
`predetermined quantity of active material calculated to pro-
`about 19 percent, about 20 percent) of the total amount of
`duce the desired therapeutic effect, in association with a suit-
`CompoundI. In one embodiment, a pharmaceutical dosage
`able pharmaceutical excipient
`(e.g.,
`a tablet, capsule,
`form comprises about 400 mg of Compound I, wherein the
`ampoule). The compounds are generally administered in a
`amountof Form 8 is from about 1 to about 100 percent of the
`pharmaceutically effective amount. In some embodiments,
`total amount of CompoundI. In one embodiment, a pharma-
`each dosage unit contains from 1 mg to 2 g of a CompoundI,
`ceutical dosage form comprises about 400 mg of Compound
`Form 7 or Form 8, and for parenteral administration, in some
`I, wherein the amount of Form 8 is from about 1 to about 40
`embodiments, from 0.1 to 700 mg of CompoundI, Form 7 or
`percent of the total amount of CompoundI. In one embodi-
`Form 8. In some embodiments, each dosage unit contains
`ment, a pharmaceutical dosage form comprises about 400 mg
`about 400 mg of CompoundI, Form 7 or Form 8. It will be
`of CompoundI, wherein the amount of Form 8 is from about
`understood, however, that the amount of the compound actu-
`1 to about 20 percent (i.e. about 1 percent, about 2 percent,
`ally administered usually will be determined by a physician,
`about 3 percent, about 4 percent, about 5 percent, about 6
`in the light of the relevant circumstances, including the con-
`dition to be treated, the chosen route of administration, the
`percent, about 7 percent, about 8 percent, about 9 percent,
`about 10 percent, about 11 percent, about 12 percent, about 13
`actual compound administered and its relative activity, the
`percent, about 14 percent, about 15 percent, about 16 percent,
`age, weight and responseofthe individual subject, the sever-
`about 17 percent, about 18 percent, about 19 percent, about 20
`ity of the subject’s symptoms, andthe like.
`percent) of the total amount of CompoundI.
`For preparing solid compositions suchas tablets,the prin-
`CompoundI, Form 7 or Form 8 described herein may be
`cipal active ingredient is mixed with a pharmaceutical excipi-
`administered to a human subject suffering from hepatitis C
`ent to form a solid preformulation composition containing a
`virus (HCV)in either single or multiple doses by any of the
`homogeneous mixture of a compoundofthe present disclo-
`accepted modes of administration known to those who are
`sure. Whenreferring to these preformulation compositions as
`skilled in the art and as detailed above. In one embodiment,
`homogeneous, it is meant that the active ingredient is dis-
`provided herein is a method of treating a human subject
`persed evenly throughout the composition so that the compo-
`infected with hepatitis C virus comprising administering to
`sition may be readily subdivided into equally effective unit
`the humansubject a therapeutically effective amount of Com-
`dosage forms such astablets, pills and capsules.
`poundI Form 7. In another embodiment, provided hereinis a
`Thetabletsor pills of the present disclosure may be coated
`methodoftreating a human subject infected with hepatitis C
`or otherwise compoundedto provide a dosage form affording
`virus comprising administering to the human subjecta thera-
`the advantage of prolonged action or to protect from the acid
`peutically effective amount of Compound I, Form 8. In
`conditions of the stomach. For example, the tablet or pill can
`another embodiment, provided herein is a methodoftreating
`comprise an inner dosage and an outer dosage component,the
`a human subject infected with hepatitis C virus comprising
`latter being in the form of an envelope over the former. The
`administering to the human subject a pharmaceutical compo-
`two components can be separated by an enteric layer that
`sition comprising a therapeutically effective amount of Com-
`serves to resist disintegration in the stomach and permit the
`
`inner componentto pass intact into the duodenum orto be pound I, Form 7 andapharmaceutically acceptable carrier. In
`delayed in release. A variety ofmaterials can